123 related articles for article (PubMed ID: 9095665)
1. [Hypereosinophilia after allogeneic bone marrow transplantation. A possible role of IL-5 overproduction by donor T-cells chronic GVHD].
Masumoto A; Sasao T; Yoshiba F; Kato S; Mori A; Okudaira H; Hotta T
Rinsho Ketsueki; 1997 Mar; 38(3):234-6. PubMed ID: 9095665
[TBL] [Abstract][Full Text] [Related]
2. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
3. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
4. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
5. Predicting the severity of graft-versus-host disease from interleukin-10 levels after bone marrow transplantation.
Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Yamada S; Kanamaru A; Kakishita E
Bone Marrow Transplant; 1999 Nov; 24(9):1005-7. PubMed ID: 10556960
[TBL] [Abstract][Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
8. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
10. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
12. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.
Imoto S; Oomoto Y; Murata K; Das H; Murayama T; Kajimoto K; Sugimoto T; Gomyo H; Nakagawa T; Nishimura R; Koizumi T
Int J Hematol; 2000 Jul; 72(1):92-7. PubMed ID: 10979216
[TBL] [Abstract][Full Text] [Related]
14. [Secondary eosinophilia in a patient with hypereosinophilic syndrome after allogeneic bone marrow transplantation from a sibling donor].
Ito C; Tsuboi K; Yoshiba F; Kubota N; Tazume K; Oki M; Tsuchiya T; Ohmachi K; Kikuchi A; Shimakura Y; Ando K; Kishi K; Yonekura S; Hotta T
Rinsho Ketsueki; 2001 Jun; 42(6):496-501. PubMed ID: 11505529
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
17. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
18. The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation.
Hildebrandt GC; Choi SW; Mueller G; Olkiewicz KM; Moore BB; Cooke KR
Pediatr Blood Cancer; 2008 Apr; 50(4):911-4. PubMed ID: 17455319
[TBL] [Abstract][Full Text] [Related]
19. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
20. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]